Cam Gallagher - Jan 17, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
President, Director
Signature
By: /s/ Melissa B. Epperly, attorney-in-fact for Cam S. Gallagher
Stock symbol
ZNTL
Transactions as of
Jan 17, 2023
Transactions value $
-$241,515
Form type
4
Date filed
1/18/2023, 04:15 PM
Previous filing
Jan 5, 2023
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$229K -9.5K -2.62% $24.11 353K Jan 17, 2023 Direct F1, F2
transaction ZNTL Common Stock Sale -$12.4K -500 -0.14% $24.87 352K Jan 17, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.76 to $24.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.78 to $24.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.